mProX™ Human VSIR Stable Cell Line

Product Information

Target Family

Immune Checkpoint

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;MDA-MB-468

Target Classification

Immune Checkpoint Cell Lines

Target Research Area

Cancer Research

Related Diseases

Hard Palate Cancer

Gene ID

Human:64115

UniProt ID

Human:Q9H7M9

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

V-domain immunoglobulin suppressor of T-cell activation (VISTA) is an immune checkpoint protein that plays a role in immunoregulation. It has been found to have applications in various diseases, including systemic lupus erythematosus (SLE), melanoma, adenocarcinoma, and neuroendocrine tumors. In SLE, VISTA deficiency exacerbates the disease, while enhancing VISTA function through small-molecule agonists like imatinib and M351-0056 can ameliorate SLE development. In melanoma and adenocarcinoma murine models, blocking VISTA with antibodies or genetic knockout combined with radiation therapy improves tumor control ability. In neuroendocrine tumors, VISTA is associated with tumor pathophysiology, and its blockade may have potential therapeutic implications. Additionally, VISTA expression has been studied in triple-negative breast cancer and malignant uveal melanoma, where it is associated with prognosis and may serve as a marker for immunotherapy response. Overall, VISTA has emerged as an important target for therapeutic interventions in various diseases.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human VSIR Stable Cell Line (S01YF-1023-PY185). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Alex Brown (Verified Customer)

What is the role of VSIR in cancer immunotherapy? Oct 29 2023

chat Patrick Liam (Creative Biolabs Scientific Support)

VSIR (V-domain Ig suppressor of T cell activation) plays a significant role in the tumor microenvironment, influencing clinical outcomes and tumor immunity in various cancers. Therapeutic strategies targeting VSIR may offer valuable tools for cancer immunotherapy. Oct 29 2023

chat Morgan Miller (Verified Customer)

How does VSIR expression affect prognosis in acute myeloid leukemia? Jan 01 2022

chat Patrick Liam (Creative Biolabs Scientific Support)

The prognostic value of VSIR in acute myeloid leukemia and myelodysplastic syndromes is debated, with its expression showing conflicting roles in cancer immunity. Jan 01 2022

Published Data

Fig.1 VISTA antibody validation on MDA-MB-468 cells using IHC on scrambled control and siRNA against VSIR gene.

A transient knockdown of the VSIR gene was executed on the breast cancer cell line MDA-MB-468 to examine the specificity of the VISTA antibody. Extensively utilized and well-characterized antibodies against the remaining markers rendered re-validation unnecessary. Positive staining for the VISTA protein was observed in cells subjected to the scrambled control sequence, both at high and low magnifications. In contrast, no staining at the protein level was observed in cells exposed to the short interfering RNA sequence against VSIR.

Ref: Croft, Priyakshi Kalita-de, et al. "Characterization of immune cell subsets of tumor infiltrating lymphocytes in brain metastases." Biology 10.05 (2021): 425.

Pubmed: 34064871

DOI: 10.3390/biology10050425

Research Highlights

Yang, Lu. et al. "Imatinib and M351-0056 enhance the function of VISTA and ameliorate the development of SLE via IFN-I and noncanonical NF-Œ∫B pathway." Cell biology and toxicology, 2023.
The role of V-domain immunoglobulin suppressor of T-cell activation (VISTA), a crucial negative checkpoint protein, in immunoregulation is significant. Patients diagnosed with systemic lupus erythematosus (SLE), an autoimmune disease characterized by elevated autoantibody levels and tissue damage in multiple organs, particularly the kidney and skin, have been found to have changed levels of VISTA expression. In both wild-type (WT) mice and Vsir1 knockout (KO) mice, SLE has been linked to modified VISTA expression. The relationship between VISTA and SLE is an area of active research.
Yang, Lu. et al. "Imatinib and M351-0056 enhance the function of VISTA and ameliorate the development of SLE via IFN-I and noncanonical NF-Œ∫B pathway." Cell biology and toxicology, 2023.
Pubmed: 37804401 DOI: 10.1007/s10565-023-09833-6

E A Duval, Kayla. et al. "Enhancement of Radiation Therapy through Blockade of the Immune Checkpoint, V-domain Ig Suppressor of T Cell Activation (VISTA), in Melanoma and Adenocarcinoma Murine Models." International journal of molecular sciences, 2023.
In recent studies, radiation therapy (RT) has shown potential in stimulating an enhanced immune response. The success of immunotherapies, such as checkpoint inhibitors, CART cells, and other immune modulators, has opened up new opportunities for combination with RT. The objective of this study is to investigate whether and to what extent blockade of VISTA, an immune checkpoint, can boost the tumor control capability of RT. This research is unique as it is the first to compare two methods of VISTA blocking (antibody inhibition and genetic knockout) in combination with RT. The experiments were conducted on two syngeneic murine flank tumor models (B16 and MC38) and involved the assessment of mRNA, immune cell infiltration, and tumor growth delay to determine the biological effects. Results showed that when combined with a single 15Gy radiation dose, VISTA blockade through genetic knockout in the B16 model and through anti-VISTA antibodies in the MC38 model significantly improved survival compared to RT alone, with an average increase in survival of 5.5 and 6.3 days, respectively (R).
E A Duval, Kayla. et al. "Enhancement of Radiation Therapy through Blockade of the Immune Checkpoint, V-domain Ig Suppressor of T Cell Activation (VISTA), in Melanoma and Adenocarcinoma Murine Models." International journal of molecular sciences, 2023.
Pubmed: 37762046 DOI: 10.3390/ijms241813742